|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
Q2 FY2021
As of Jun 30, 2021
|
Q1 FY2021
As of Mar 31, 2021
|
Q4 FY2020
As of Dec 31, 2020
|
Q3 FY2020
As of Sep 30, 2020
|
Q2 FY2020
As of Jun 30, 2020
|
Q1 FY2020
As of Mar 31, 2020
|
Q4 FY2019
As of Dec 31, 2019
|
Q3 FY2019
As of Sep 30, 2019
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalents | ||||||||||||||||||||
| Short-term investments | ||||||||||||||||||||
| Accounts receivable | ||||||||||||||||||||
| Inventories | ||||||||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||||||||
| Current Assets | ||||||||||||||||||||
| Long-term investments | ||||||||||||||||||||
| Property, plant and equipment | ||||||||||||||||||||
| Less accumulated depreciation and amortization | ||||||||||||||||||||
| Property, Plant and Equipment, Net | ||||||||||||||||||||
| Patents | ||||||||||||||||||||
| Other assets and deferred charges: | ||||||||||||||||||||
| Patents and licenses | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Total Non- Current Assets | ||||||||||||||||||||
| Other | ||||||||||||||||||||
| Other assets and deferred charges | ||||||||||||||||||||
| Prepaid Expense and Other Assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Current liabilities: | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accrued liabilities | ||||||||||||||||||||
| Accounts payable and accrued liabilities | ||||||||||||||||||||
| Accrued income and other taxes | ||||||||||||||||||||
| Liabilities, Current | ||||||||||||||||||||
| Line of credit | ||||||||||||||||||||
| Deferred income taxes | ||||||||||||||||||||
| Other | ||||||||||||||||||||
| Other liabilities and deferred credits | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Other non-current liabilities | ||||||||||||||||||||
| Stockholders' equity: | ||||||||||||||||||||
| Common stock, par value $0.10 per share; authorized 10,000 shares, issued 3,420 shares | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Treasury shares, 1,619 shares in 2021 and 1,594 shares in 2020, at cost | ||||||||||||||||||||
| Treasury shares,1,660 at June 30, 2024 and 1,660 at December 31, 2023, at cost | ||||||||||||||||||||
| Total stockholders' equity | ||||||||||||||||||||
| Total liabilities and stockholders' equity | ||||||||||||||||||||
Loading...
